Background: Dupilumab, targeting the interleukin-4allpha receptor and inhibiting the action of interleukin-4 and\ninterleukin-13, was recently approved for treatment of moderate to severe atopic dermatitis. There is limited data\non long-term effects and safety among patients with severe atopic dermatitis treated with dupilumab. Weight gain\nwas observed among patients treated with dupilumab in our clinic. The aim was to describe weight change in\na cohort study of patients with severe atopic dermatitis treated with dupilumab from baseline to follow-up after\n12 months, and to analyze if weight change was associated with effect of treatment, reported appetite, and/or\ndisturbed night sleep due to itching.\nMethods: All patients with atopic dermatitis receiving systemic treatment at the Unit of Dermatology, Karolinska\nUniversity Hospital, have been registered and monitored consecutively since January 2017. This cohort constituted\nall patients who started treatment on dupilumab or methotrexate between 10 January 2017 and 30 June 2019 with\nat least 6 months of follow-up within the study period.........................
Loading....